Central Trust Company’s NovoCure NVCR Stock Holding History

Central Trust Company’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-18	Closed	-$282	–	1440
2024 Q1	$282	Hold	18	–	–	﹤0.01%	1356
2023 Q4	$269	Buy	+18	New	+$241	﹤0.01%	1364
2023 Q2	–	Sell	-20	Closed	-$1.2K	–	1273
2023 Q1	$1.2K	Hold	20	–	–	﹤0.01%	1212
2022 Q4	$1.47K	Hold	20	–	–	﹤0.01%	1181
2022 Q3	$2K	Hold	20	–	–	﹤0.01%	1212
2022 Q2	$1K	Sell	20 -100	-83%	-$7.53K	﹤0.01%	1313
2022 Q1	$10K	Buy	120 +80	+200%	+$5.89K	﹤0.01%	1079
2021 Q4	$3K	Sell	40 -10	-20%	-$1K	﹤0.01%	1177
2021 Q3	$6K	Hold	50	–	–	﹤0.01%	1098
2021 Q2	$11K	Sell	50 -40	-44%	-$7.78K	﹤0.01%	1005
2021 Q1	$12K	Sell	90 -20	-18%	-$3.16K	﹤0.01%	906
2020 Q4	$19K	Sell	110 -40	-27%	-$5.47K	﹤0.01%	812
2020 Q3	$17K	Sell	150 -180	-55%	-$14.4K	﹤0.01%	789
2020 Q2	$20K	Hold	330	–	–	﹤0.01%	743
2020 Q1	$22K	Buy	330 +200	+154%	+$15.8K	﹤0.01%	743
2019 Q4	$11K	Hold	130	–	–	﹤0.01%	934
2019 Q3	$10K	Buy	+130	New	+$10.4K	﹤0.01%	904

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Central Trust Company's NVCR Position: Q2 2024 in Review

Central Trust Company sold out of NovoCure (NVCR) in Q2 2024, closing a stake of 18 shares — an estimated $282 sold.

Central Trust Company first reported a position in NVCR in Q3 2019 and held it in 17 quarters. The position peaked at $22K in Q1 2020. 236 funds tracked by Wall St. Rank hold NVCR as of Q2 2024.

Central Trust Company reported no remaining NovoCure position as of Q2 2024 after selling out during the quarter.
Central Trust Company sold 18 NovoCure shares in Q2 2024, an estimated $282.
Central Trust Company first reported a position in NovoCure in Q3 2019 and held it in 17 quarters.
Central Trust Company's NovoCure position peaked at $22K in Q1 2020.
236 funds tracked by Wall St. Rank held NovoCure as of Q2 2024.

Based on Central Trust Company's 13F filing for Q2 2024, filed 5 Aug 2024.